期刊文献+

培菲康联合奥沙拉嗪治疗溃疡性结肠炎疗效观察 被引量:5

Clinical Effect of Bifico Combined Olsalazine in Treating Ulcerative Colitis
暂未订购
导出
摘要 目的观察培菲康联合奥沙拉嗪治疗溃疡性结肠炎的临床疗效。方法肠镜确诊43例轻、中度溃疡性结肠炎患者随机分为治疗组(22例)和对照组(21例)。治疗组给予培菲康420 mg,口服,3次/d;奥沙拉嗪1.0,口服,4次/d。对照组予奥沙拉嗪1.0,口服,4次/d;疗程均为8周。治疗后,进行症状评分,复查肠镜取病理观察组织学变化。结果显效率、总有效率治疗组分别为40.9%和90.9%,对照组分别为28.6%和76.2%,经χ2检验差异均有显著意义(P<0.05)。结论培菲康联合奥沙拉嗪治疗溃疡性结肠炎的疗效优于单用奥沙拉嗪。 Objective To Observe the clinical efficacy of bifico combined Olsalazine in the treatment of ulcerative colitis. Methods 43 cases of mild to moderate ulcerative colitis who diagnosed by Colonoscopy were randomly divided into treatment group (22 cases) and control group (21 cases). Treatment group was given bifico 420mg, orally, three times a day, olsalazine 1.0, orally, four times a day; The control group were given Olsalazine 1.0, orally, four times a day; treatment were 8 weeks. Symptom score were recorded after treatment. We reviewed colonoscopy and and raked patholog- ical histological changes. Results Excellence rate, the total effective rate were 40.9 % and 90.9%. In control group was 28.6% and 76.2% ( P 〈 0.05). Conclusion Bifico combined olsalazine treatment of ulcerative colitis is better than alone olsalazine.
作者 刘刚
出处 《黑龙江医学》 2009年第12期932-933,共2页 Heilongjiang Medical Journal
关键词 培菲康 奥沙拉嗪 溃疡性结肠炎 Bifico Olsalazine Ulcerative colitis
  • 相关文献

参考文献4

二级参考文献19

  • 1霍丽娟,赵和平.益生菌对溃疡性结肠炎大鼠结肠黏膜中IL-1和TNFα表达的影响[J].山西医科大学学报,2004,35(4):341-343. 被引量:16
  • 2溃疡性结肠炎的诊断及疗效标准[J].中华消化杂志,1993,13(6):354-354. 被引量:1064
  • 3MacDonald TT, Monteleone G, Render SL. Recent developments in immunology of Inflammatory bowel disease. Scand-J-Immunol, 2000,51 ( 1 ) : 2 - 9.
  • 4Linskens RK,Huijsdens XW,Savelkoul PH.et al. Thebacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol, 2001,36 ( Suppl 234 ) :29 -40.
  • 5Balish E, Warner T. Enteroeoecus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol, 2002, 160 ( 6 ) : 2253-2257.
  • 6Malin M. Suomalainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab, 1996,40(3):137-145.
  • 7Kim PH, Ko EJ. Bifidobacterium is a strong stimulant for IgA antibody production by mucosal B lymphocytes. FASEB J, 1998,12 ( 4 Suppl) : A5278.
  • 8Shanahan, F. Probiotics and inflammatory bowel disease: Is there a scientific tationale? Inflamm Bowel Dis,2000,6(2) : 107-115.
  • 9Fuller R.Probiotics in human medicine[J].Gut,1991,32:439-442.
  • 10Dotan I,Rachmilewitz D.Probiotics in inflammatory bowel disease:possible mechanisms of action[J].Curr Opin Gastroenterol,2005,21 (4):426-430.

共引文献53

同被引文献58

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部